ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+2.32%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$7.07B
AUM Growth
+$7.07B
(+3.1%)
Cap. Flow
+$370M
Cap. Flow
% of AUM
5.23%
Top 10 Holdings %
Top 10 Hldgs %
69.18%
Holding
43
New
7
Increased
10
Reduced
7
Closed
3
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$103M |
| 2 |
Alkermes
ALKS
|
$70.5M |
| 3 |
Vera Therapeutics
VERA
|
$55M |
| 4 |
Arrowhead Research
ARWR
|
$41.8M |
| 5 |
uniQure
QURE
|
$38.4M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$37.8M |
| 2 |
United Therapeutics
UTHR
|
$34.8M |
| 3 |
Dyne Therapeutics
DYN
|
$23.3M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$21.3M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$13.8B
| $974M | 13.78% | 2,760,300 -98,588 | -3% | -$34.8M |
|
2
argenx
ARGX
$43.6B
| $762M | 10.77% | 1,238,467 | – | – |
|
3
Ascendis Pharma
ASND
$11.8B
| $703M | 9.94% | 5,103,055 +114,167 | +2% | +$15.7M |
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $626M | 8.86% | 2,029,000 | – | – |
|
5
Krystal Biotech
KRYS
$4.27B
| $412M | 5.83% | 2,628,822 +6,600 | +0.3% | +$1.03M |
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $390M | 5.52% | 12,222,222 +1,111,111 | +10% | +$35.5M |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $311M | 4.4% | 2,555,555 | – | – |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $255M | 3.6% | 3,050,000 | – | – |
|
|
9
Vera Therapeutics
VERA
$1.38B
| $237M | 3.36% | 5,610,000 +1,300,410 | +30% | +$55M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $222M | 3.14% | 5,666,666 | – | – |
|
11
Amicus Therapeutics
FOLD
$2.34B
| $218M | 3.09% | 23,175,000 | – | – |
|
12
Avidity Biosciences
RNA
$5.99B
| $218M | 3.08% | 7,500,000 +625,000 | +9% | +$18.2M |
|
|
13
Arrowhead Research
ARWR
$3.05B
| $209M | 2.95% | 11,111,111 +2,222,223 | +25% | +$41.8M |
|
14
Kymera Therapeutics
KYMR
$2.95B
| $207M | 2.93% | 5,150,000 +650,000 | +14% | +$26.1M |
|
15
MoonLake Immunotherapeutics
MLTX
$3.54B
| $150M | 2.12% | 2,770,100 | – | – |
|
16
Soleno Therapeutics
SLNO
$3.6B
| $113M | 1.61% | 2,525,000 +344,000 | +16% | +$15.5M |
|
|
BPMC
17
DELISTED
Blueprint Medicines
BPMC
| $103M | 1.46% | +1,185,000 | New | +$103M |
|
18
Vaxcyte
PCVX
$4B
| $96.2M | 1.36% | 1,175,000 | – | – |
|
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $96.1M | 1.36% | 1,462,500 -575,515 | -28% | -$37.8M |
|
20
Merus
MRUS
$4.98B
| $89.4M | 1.26% | 2,125,000 +770,000 | +57% | +$32.4M |
|
21
BioCryst Pharmaceuticals
BCRX
$1.74B
| $89.2M | 1.26% | 11,865,000 | – | – |
|
|
22
Alkermes
ALKS
$4.78B
| $70.5M | 1% | +2,450,000 | New | +$70.5M |
|
23
Ocular Therapeutix
OCUL
$2.12B
| $68.8M | 0.97% | 8,060,000 | – | – |
|
24
MannKind Corp
MNKD
$1.41B
| $56.3M | 0.8% | 8,750,000 | – | – |
|
25
Tourmaline Bio
TRML
$601M
| $45.1M | 0.64% | 2,222,222 | – | – |
|